In the News
January 20, 2023
LEX Diagnostics’ new CEO gets a warm welcome at Melbourn Science Park
The new CEO of LEX Diagnostics, Ed Farrell, has spoken of the Melbourn Science Park-based company’s ambition: ‘Revolutionising molecular point-of-care diagnostics with a step change in speed, sensitivity, and cost’.
LEX was incubated by the TTP Group on Melbourn Science Park.
For more than 20 years, TTP had been developing a series of successful point-of-care instruments across immunology, histology and diagnostics. In 2017, TTP, realising that mass adoption of molecular diagnostics at the point-of-care needed a step-change improvement, initiated an internal development programme to optimise PCR (polymerase chain reaction) hardware for point-of-care applications.
In 2018, the group completed development of a low-cost PCR system for consumer genetic advice for London-centred DnaNudge.
Following the successful technology demonstration, TTP Group invested core intellectual property and key staff into a dedicated company with a mission to commercialise an ultrafast point-of-care diagnostic for respiratory viruses: LEX Diagnostics was founded in 2020 as a privately-held UK molecular diagnostics company.
The mission LEX was entrusted with involved developing a 5-minute multiplex PCR test designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable.
After being founded in February 2020, LEX spent the rest of the year expanding the scientific team and building new facilities, focusing on custom reagent development, bioinformatics and the manufacture of medical consumables.
From left at LEX Diagnostics on Melbourn Science Park are Chairman of the Board Andrew Baker-Campbell and new CEO Ed Farrell. Picture: Keith Heppell
For more than 20 years, TTP had been developing a series of successful point-of-care instruments across immunology, histology and diagnostics. In 2017, TTP, realising that mass adoption of molecular diagnostics at the point-of-care needed a step-change improvement, initiated an internal development programme to optimise PCR (polymerase chain reaction) hardware for point-of-care applications.
In 2018, the group completed development of a low-cost PCR system for consumer genetic advice for London-centred DnaNudge.
Following the successful technology demonstration, TTP Group invested core intellectual property and key staff into a dedicated company with a mission to commercialise an ultrafast point-of-care diagnostic for respiratory viruses: LEX Diagnostics was founded in 2020 as a privately-held UK molecular diagnostics company.
The mission LEX was entrusted with involved developing a 5-minute multiplex PCR test designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable.
After being founded in February 2020, LEX spent the rest of the year expanding the scientific team and building new facilities, focusing on custom reagent development, bioinformatics and the manufacture of medical consumables.
From left at LEX Diagnostics on Melbourn Science Park are Chairman of the Board Andrew Baker-Campbell and new CEO Ed Farrell. Picture: Keith Heppell